CMND Secures Exclusive Rights for PTSD Treatment, and Announces Licensing Agreement for Mental Disorders
Vancouver, Canada - Clearmind Medicine Inc. a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics, is making significant strides in its mission to address under-treated health problems. The company has recently signed several strategic agreements and licensing partnerships that showcase its commitment to expanding its product portfolio and improving mental health treatment.
To kickstart its international expansion, Clearmind Medicine has entered into a strategic engagement with JS First Sdn. Bhd (JS First), a renowned partner in the global manufacturing and distribution industry. This collaboration seeks to find manufacturers and distributors for Clearmind’s groundbreaking MEAI-based alcohol substitute beverages. By harnessing the potential of psychedelic-derived compounds, Clearmind aims to provide consumers with a safe and healthier alternative to traditional alcoholic beverages. The partnership with JS First is a crucial step towards achieving this goal and expanding the company’s reach into global markets.
In addition to its efforts in the beverage industry, Clearmind Medicine has also secured exclusive global rights to innovative psychedelic compounds specifically designed for the treatment of post-traumatic stress disorder (PTSD) and other mental health conditions. Through an exclusive patent licensing agreement with the Yissum Research Development Company of the Hebrew University of Jerusalem, Clearmind has gained the rights to further develop, manufacture, and commercialize the compounds invented by esteemed professors Rami Yaka, Ahmed Masaewa, and Avi Priel. This groundbreaking agreement positions Clearmind at the forefront of advancing psychedelic therapeutics for mental health treatment.
Furthermore, Clearmind Medicine recently announced another exclusive licensing agreement with Yissum Research Development Company. This partnership aims to utilize generation 3.0 psychedelic compounds, their preparation methods, and their applications in treating addiction and mental disorders. The collaboration with Yissum Research Development Company reinforces Clearmind’s commitment to developing cutting-edge solutions for under-treated health problems and revolutionizing the field of mental health therapeutics.
With these significant developments, Clearmind Medicine is poised to make a lasting impact on the biotech industry. By expanding its product portfolio through the partnership with JS First, Clearmind aims to provide individuals with a safe and effective alcohol substitute beverage that can potentially reduce the harms associated with excessive alcohol consumption. Simultaneously, the exclusive global rights acquired for innovative compounds for the treatment of PTSD and the licensing agreement for generation 3.0 psychedelic compounds solidify Clearmind as a frontrunner in revolutionizing mental health treatment.
Comments